Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Robinson

Showing results (51-60 of 140) with videos related to

Pageof 14
Sort By:
Cell Cycle (Georgetown, Tex.)|April 4, 2007
DNA mismatch repair and Chk1-dependent centrosome amplification in response to DNA alkylation damageHelen M R Robinson, Elizabeth J Black, Robert Brown, et al.
British Journal of Urology|December 1, 1983
Low-dose doxorubicin in the management of advanced carcinoma of the prostateM R Robinson, S Chandrysekran, D W Newling, et al.
Cell Cycle (Georgetown, Tex.)|May 15, 2007
Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193Helen M R Robinson, Sigrid Bratlie-Thoresen, Robert Brown, et al.
European Urology|July 21, 2001
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion studyD W Newling, J Hetherington, S K Sundaram, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 2, 1981
The evaluation of a new enzyme immunoassay for the measurement of prostatic acid phosphataseE H Cooper, R Glashan, M R Robinson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1985
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injectionsM R Robinson, L Denis, C Mahler, et al.
Progress in Clinical and Biological Research|January 1, 1985
Proteinuria after intravesical chemotherapyE H Cooper, H Yu, R W Glashan, et al.
Progress in Clinical and Biological Research|January 1, 1985
The EORTC Phase III trials in prostatic cancerM R Robinson, P H Smith, M P Macaluso, et al.
British Journal of Urology|December 1, 1988
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancerT G Armitage, E H Cooper, D W Newling, et al.
American Journal of Ophthalmology|March 10, 2001
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitisG Velez, C E Roy, S M Whitcup, et al.
Pageof 14

Showing results (51-60 of 140) with videos related to

Sort By:
Pageof 14
Cell Cycle (Georgetown, Tex.)|April 4, 2007
DNA mismatch repair and Chk1-dependent centrosome amplification in response to DNA alkylation damageHelen M R Robinson, Elizabeth J Black, Robert Brown, et al.
British Journal of Urology|December 1, 1983
Low-dose doxorubicin in the management of advanced carcinoma of the prostateM R Robinson, S Chandrysekran, D W Newling, et al.
Cell Cycle (Georgetown, Tex.)|May 15, 2007
Chk1 is required for G2/M checkpoint response induced by the catalytic topoisomerase II inhibitor ICRF-193Helen M R Robinson, Sigrid Bratlie-Thoresen, Robert Brown, et al.
European Urology|July 21, 2001
The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion studyD W Newling, J Hetherington, S K Sundaram, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 2, 1981
The evaluation of a new enzyme immunoassay for the measurement of prostatic acid phosphataseE H Cooper, R Glashan, M R Robinson, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1985
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injectionsM R Robinson, L Denis, C Mahler, et al.
Progress in Clinical and Biological Research|January 1, 1985
Proteinuria after intravesical chemotherapyE H Cooper, H Yu, R W Glashan, et al.
Progress in Clinical and Biological Research|January 1, 1985
The EORTC Phase III trials in prostatic cancerM R Robinson, P H Smith, M P Macaluso, et al.
British Journal of Urology|December 1, 1988
The value of the measurement of serum prostate specific antigen in patients with benign prostatic hyperplasia and untreated prostate cancerT G Armitage, E H Cooper, D W Newling, et al.
American Journal of Ophthalmology|March 10, 2001
High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitisG Velez, C E Roy, S M Whitcup, et al.
Pageof 14